About Type-1 angiotensin II receptor
Type-1 angiotensin II receptor (AGTR1) is a protein
from Homo sapiens identified by UniProt accession
P30556, 359 residues long.
MolForge cross-references it against 0 known binders and
972 disease associations.
Target properties
| Protein name | Type-1 angiotensin II receptor |
|---|
| UniProt accession | P30556 |
|---|
| Gene | AGTR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 359 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (13)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (972)
Diseases linked to this target (Open Targets).
- hypertension · score 0.75
- renal tubular dysgenesis · score 0.69
- essential hypertension · score 0.67
- kidney disease · score 0.62
- myocardial infarction · score 0.61
- heart failure · score 0.61
- stroke · score 0.60
- congestive heart failure · score 0.60
- diabetes mellitus · score 0.60
- diabetic nephropathy · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30556-F1 | alphafold | PREDICTED | 82.33 | — |
Amino-acid sequence (359 residues)
MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFGNSLVV IVIYFYMKLK TVASVFLLNL ALADLCFLLT LPLWAVYTAM EYRWPFGNYL CKIASASVSF NLYASVFLLT CLSIDRYLAI VHPMKSRLRR TMLVAKVTCI IIWLLAGLAS LPAIIHRNVF FIENTNITVC AFHYESQNST LPIGLGLTKN ILGFLFPFLI ILTSYTLIWK ALKKAYEIQK NKPRNDDIFK IIMAIVLFFF FSWIPHQIFT FLDVLIQLGI IRDCRIADIV DTAMPITICI AYFNNCLNPL FYGFLGKKFK RYFLQLLKYI PPKAKSHSNL STKMSTLSYR PSDNVSSSTK KPAPCFEVE
Explore Type-1 angiotensin II receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets